Tagged with R&D,

Denmark As Denmark positions itself as a rising force in global life sciences, the BioInnovation Institute (BII) stands at the centre of this momentum, bridging world-class academic research with entrepreneurial ambition. In this conversation, CEO Jens Nielsen shares how BII is scaling its proven model, shaping Denmark’s innovation environment, and drawing…

Switzerland Switzerland is a crucial country for MSD’s global network, employing over 1000 people in local, regional, and global functions across four sites in Lucerne and a newly opened site in Zurich specialising in R&D, data management, and commercialisation. With 25 ongoing clinical trials per year, Switzerland is an important country…

Switzerland As global science faces mounting complexity, the Paul Scherrer Institute (PSI) stands out as a model of long-term vision, technical excellence, and interdisciplinary ambition. Director Christian Rüegg discusses how PSI is advancing the frontiers of oncology, neuroscience, energy, and AI – developing radiopharmaceuticals and imaging entire neural networks, to enabling…

USA Manuel Guzman, President of CAS, a division of the American Chemical Society, outlines the organization’s vital role in scientific knowledge management and its commitment to accelerating breakthroughs in biomedical research. In this interview, Guzman delves into CAS’s strategic partnership with Cleveland Clinic, the impact of AI and quantum computing in…

Denmark Maja Kramp, General Manager at Ferring Nordics, discusses the company’s long-standing commitment to innovation in reproductive medicine and the pivotal role of the Nordic region in Ferring’s global strategy. She highlights the region’s strong life sciences ecosystem, Denmark’s leadership in global R&D, and the company’s values of collaboration, care, and…

Investment In a year marked by uncertainty and tighter capital flows, the competition to attract life sciences investment has never been fiercer. Global hubs are not just showcasing infrastructure or talent – they’re fighting for the soul, and pockets, of the industry’s future. We spoke to the CEOs of regional investment…

USA As the search for effective Alzheimer’s treatments continues to evolve, Annovis Bio is taking a distinct approach with buntanetap, a novel oral candidate designed to intervene more broadly in disease progression. In this interview, Chief Business Officer Mark White discusses the company’s clinical learnings, operational discipline, and the realities of…

Global As the neuroscience field gains unprecedented momentum, Roche is taking a leading role in redefining how neurodegenerative diseases like Alzheimer’s are understood, diagnosed, and treated. Dr Azad Bonni, Senior Vice President and Global Head of Neuroscience and Rare Diseases at Roche’s Pharma Research and Early Development (pRED), brings a unique…

Hong Kong At the Centre for Oncology and Immunology, a flagship of Hong Kong’s Health@InnoHK initiative, science converges across disciplines and continents. Under the leadership of Professor Tak Wah Mak, the Centre is advancing a new understanding of how immune responses are shaped, not only by tumours, but by the nervous system…

Hong Kong In recent years, the Hong Kong Institute of Biotechnology (HKIB) has entered a new phase, shifting from the groundwork of facility-building to the clinical delivery of locally manufactured CAR-T therapies. Managing Director Gina Jiang reflects on this transition and shares how early operational lessons are in forming a wider platform…

Hong Kong For anyone seeking a place where world-class science and a balanced lifestyle can coexist, Hong Kong offers a uniquely compelling proposition. As China’s pharmaceutical landscape expands into innovative biologics, SPH Biotherapeutics (HK) – an R&D affiliate of Shanghai Pharma – is advancing a dual-targeting CAR-T platform with early clinical results…

Research Andreas Lysandropoulos, Senior Vice President and Global Therapeutic Area Head for Neuroscience at Parexel, shares his insights on the evolving landscape of clinical development for neurological conditions. In this interview, he highlights the importance of localised patient engagement, the role of advocacy in building urgency around diseases like Alzheimer’s, and…